- Zacks
STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
Shattuck stock plunges as it discontinues the clinical development of SL-172154 for two blood cancer indications and plans to reduce the workforce by 40%.
- Zacks
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.
- Insider Monkey
Bristol-Myers Squibb Company (BMY) is Driving Growth Through Strategic Acquisitions
We recently published a list of Dividend Achievers List: Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other dividend achievers. Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors. Companies that consistently raise their […]
